Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Stock Incentive Plan (Tables)

Note 5 - Stock Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		*Options Outstanding*
		*Number of Shares Subject to Options*				*Weighted-Average Exercise Price*
Balances as of December 31, 2022			1,642,950				4.28
Granted⁽¹⁾			508,902				3.14
Forfeited⁽²⁾			(37,851	)			4.10
Balances as of June 30, 2023			2,114,001				4.01
Unvested options outstanding expected to vest⁽³⁾			768,496				3.44

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise Prices		Number of Shares Subject to Options Outstanding				Weighted-Average Remaining Contractual Term in Years				Number of Shares Subject to Options Fully Vested and Exercisable				Weighted-Average Remaining Contractual Term in Years
$0.001 - $5.00			1,376,895				7.43				698,533				5.68
$5.01 - $10.00			617,942				6.01				530,365				5.71
$10.01 - $15.00			113,039				6.59				110,482				6.59
$15.01 - $20.00			6,125				6.59				6,125				6.59
			2,114,001				6.97				1,345,505				5.77

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

						*Weighted- Average*
		*Restricted*				*Grant Date*
		*Stock Units*				*Fair Value*
		*(#)*				*per Unit ($)*
Unvested balance as of December 31, 2022			272,650				4.00
Granted			368,345				3.16
Vested			(115,430	)			4.05
Unvested Balance as of June 30, 2023			525,565				3.40

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

		*Three Months Ended June 30,*								*Six Months Ended June 30,*
		*2023*				*2022*				*2023*				*2022*

Stock options granted			—				25,000				508,902				578,064
Weighted-average grant date fair value per share		$	—			$	2.00			$	2.38			$	2.11